Protalix BioTherapeutics (PLX) Issues Positive Update on PRX-102 Phase I/II; Improvements of Stabilization Noted
- Stocks decline as interest rate uncertainty, earnings weigh
- ASML slides as Q1 sales fall short but firm still on track for 2025 revenue target
- US dollar weakens as market consolidates gains, but uptrend intact
- Abbott Laboratories (ABT) narrows 2024 earnings guidance, shares slip
- Stocks have priced in much of the 2024 optimism - Wells Fargo
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- ICZOOM Group (IZM) Discloses Request to Withdraw Registration Statement on Form F-1
- Alaska Airlines flights resume after being grounded over aircraft system issue
- Crude Inventory Rose 2.7 Million Barrels Last Week, Says EIA
- Lithium Americas Corp (LAC) Announces Proposed 55M Share Offering
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
- After-hours movers: United Airlines, J.B. Hunt, and more
- Midday movers: Morgan Stanley, UnitedHealth rise; Tesla falls
- Morgan Stanley, UnitedHealth and Bank of America rise premarket; Tesla falls
Protalix BioTherapeutics Announces Additional Positive Data from its Phase I/II Clinical Trial for PRX-102 for the Treatment of Fabry Disease
August 10, 2016 7:30 AM EDTCARMIEL, Israel, Aug. 10, 2016 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT: PLX) (TASE: PLX), announced today additional positive data from its phase I/II clinical trial of PRX-102 for the treatment of Fabry disease.  PRX-102 is a recombinant, plant cell expressed, pegylated, modified version of the human alpha-Galactosidase-A enzyme.
We are pleased to announce additional positive results from our phase I/II Fabry clinical trial, said Moshe Manor, Protalixs President and Chief Executive Officer. The efficacy results seen to date continue to be very strong with improvements or... More